Aclaris Therapeutics Raised to Outperform From Market Perform by Leerink Partners
A Quick Look at Today's Ratings for Aclaris Therapeutics(ACRS.US), With a Forecast Between $3 to $13
Promising Potential of Aclaris Therapeutics' BSI-045B and Pipeline Elevates Buy Rating
Aclaris Therapeutics Positioned for Growth With Strategic Acquisition and Promising Pipeline
BTIG Upgrades Aclaris Therapeutics to Buy, Announces $8 Price Target
Piper Sandler: Authorized trade is transformative, significantly raising Aclaris (ACRS.US) target price to $13.
Piper Sandler has upgraded Aclaris' rating from 'neutral' to 'shareholding', and has significantly raised the target price from $3 to $13.
赚赚赚 : 4.2